Clinical trial · Observational
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
NCT06373744CI-TRIAL-00076229completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is: How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide , methotrexate , vinorelbine ,capecitabine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- metronomic chemotherapy
- description
- Patients with advanced breast cancer who received metronomic chemotherapy.
- interventionNames
- Drug: cyclophosphamide , methotrexate , vinorelbine ,capecitabine
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- Baseline up to approximately 20 months
- description
- Time from randomization to the first documentation of objective tumor progression or to death due to any cause without documented progression
Secondary outcomes (3)
- measure
- Overall Survival
- timeFrame
- Baseline until death (up to approximately 40 months)
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Females, \>18 years old; 2. Diagnosed with advanced breast cancer when using metronomic chemotherapy; 3. At least one clinical evaluation, including physical examination and imaging, according to the instructions of the supervising physician during the use of metronomic chemotherapy. Examinations include ultrasound, computed tomography, and magnetic resonance imaging; 4. Metronomic chemotherapy can be used alone, and patients who use it in combination with other drugs can also be included; 5. The clinical pathological information that needs to be collected is complete. Exclusion Criteria: 1. Taking the drug for less than 2 weeks; 2. losing follow-up after taking the therapy; 3. The patient's breast cancer was still in the early stage when taking the therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.